| human | Q5 |
| P6178 | Dimensions author ID | 01054233346.80 |
| P496 | ORCID iD | 0000-0003-1166-1966 |
| P1153 | Scopus author ID | 12042569000 |
| P735 | given name | Antoinette | Q1906662 |
| Antoinette | Q1906662 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q33848895 | 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy |
| Q37169873 | 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium |
| Q36369415 | A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis |
| Q59355837 | A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk |
| Q34613513 | A genome-wide association scan on estrogen receptor-negative breast cancer |
| Q37619303 | A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium |
| Q35870483 | A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients |
| Q57305942 | A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer |
| Q61970234 | Abstract 2793: NotHOXB13p.G84E, but p.R217C appears to be associated with increased breast cancer risk in the Dutch population |
| Q39437211 | Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers |
| Q35671197 | Analysis of TP53 mutation status in human cancer cell lines: a reassessment |
| Q35681656 | Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis |
| Q45979098 | Association analysis identifies 65 new breast cancer risk loci. |
| Q35022847 | Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies |
| Q57056093 | Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis |
| Q40333192 | BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants |
| Q38914005 | BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer |
| Q100457582 | Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk |
| Q35940158 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. |
| Q37397658 | CHEK2*1100delC homozygosity in the Netherlands--prevalence and risk of breast and lung cancer |
| Q57652970 | Comment Re: MDA-MB-435 and M14 Cell Lines: Identical but not M14 Melanoma? |
| Q35794653 | Common germline polymorphisms associated with breast cancer-specific survival |
| Q34181322 | Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer |
| Q40009249 | Deleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell lines |
| Q37719902 | Discovering moderate-risk breast cancer susceptibility genes |
| Q39826410 | Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines |
| Q34440049 | E-cadherin promotor methylation and mutation are inversely related to motility capacity of breast cancer cells |
| Q51766497 | Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. |
| Q33358687 | Exon expression arrays as a tool to identify new cancer genes |
| Q37236216 | Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). |
| Q36111237 | Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus |
| Q35524465 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. |
| Q61230414 | Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes |
| Q92480972 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes |
| Q39844032 | Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer |
| Q36248936 | Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk |
| Q34903062 | Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. |
| Q39797970 | Four human breast cancer cell lines with biallelic inactivating alpha-catenin gene mutations |
| Q114182808 | Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element |
| Q36124728 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus |
| Q39886492 | GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease. |
| Q37739048 | Genetic modifiers of CHEK2*1100delC-associated breast cancer risk |
| Q35925620 | Genetic predisposition to ductal carcinoma in situ of the breast |
| Q35151684 | Genetic predisposition to in situ and invasive lobular carcinoma of the breast |
| Q35179897 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study |
| Q36842233 | Genome-wide association analysis identifies three new breast cancer susceptibility loci |
| Q35996692 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer |
| Q63681757 | Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer |
| Q24622610 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci |
| Q95329367 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses |
| Q29417050 | Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk |
| Q64040390 | Genome-wide association study of germline variants and breast cancer-specific mortality |
| Q96432094 | Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk |
| Q114182677 | Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis |
| Q35285329 | Growth and metastatic behavior of molecularly well-characterized human breast cancer cell lines in mice |
| Q37121271 | High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium |
| Q35102646 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk |
| Q36859142 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer |
| Q36086247 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus |
| Q36014067 | Identification of novel genetic markers of breast cancer survival |
| Q46103372 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer |
| Q35104068 | Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer |
| Q29416989 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk |
| Q34556770 | Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer. |
| Q35119701 | Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium |
| Q28215462 | Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations |
| Q33483075 | Low-risk susceptibility alleles in 40 human breast cancer cell lines |
| Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
| Q30374367 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. |
| Q28584533 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS |
| Q36873786 | Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium |
| Q40168416 | Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines |
| Q62583133 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q33646928 | Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families |
| Q37350137 | Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups |
| Q34621039 | Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk |
| Q37101570 | Recurrent HOXB13 mutations in the Dutch population do not associate with increased breast cancer risk |
| Q35948726 | Representational difference analysis as a tool in the search for new tumor suppressor genes. |
| Q45951126 | Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. |
| Q35977371 | Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers |
| Q34113473 | Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy |
| Q36110285 | The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer |
| Q49817640 | The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity. |
| Q33904762 | The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype |
| Q91178389 | The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer |
| Q53686719 | The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome. |
| Q89961489 | Transcriptome-wide association study of breast cancer risk by estrogen-receptor status |
| Q41671579 | Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast cancer |
| Q36902949 | miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs |
| Q37414133 | rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk |
Search more.